$Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia$
Código QR

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph−) B-cell precursor (BCP) acute lymphoblastic leuk...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hagop M. Kantarjian, Gerhard Zugmaier, Monika Brüggemann, Brent L. Wood, Heinz A. Horst, Yi Zeng, Giovanni Martinelli
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	acute lymphoblastic leukemia bispecific antibody bispecific T-cell engager blinatumomab measurable residual disease myelosuppression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c231d049e90a4489be5d68650cd3c8ec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c231d049e90a4489be5d68650cd3c8ec
record_format	dspace
spelling	oai:doaj.org-article:c231d049e90a4489be5d68650cd3c8ec2021-11-25T17:01:27ZImpact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia10.3390/cancers132256072072-6694https://doaj.org/article/c231d049e90a4489be5d68650cd3c8ec2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5607https://doaj.org/toc/2072-6694Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph−) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL; <i>n</i> = 267) and Ph+ BCP-ALL (<i>n</i> = 45) from the TOWER and ALCANTARA studies, respectively, or chemotherapy in patients with Ph− BCP-ALL (<i>n</i> = 109) from the TOWER study; all the patients with relapsed/refractory BCP-ALL and responders achieving complete remission (CR) or CR with partial/incomplete hematological recovery (CRh/CRi) were evaluated. Event-free survival (EFS) and overall survival (OS) were assessed in patients achieving CR and CRh/CRi. Median leukocyte, neutrophil, and platelet counts increased during two blinatumomab cycles but remained low longer after chemotherapy. Among the responders, there was a trend that a greater proportion of patients achieved CR with blinatumomab (Ph−, 76.5%; Ph+, 77.8%) versus with chemotherapy (Ph−, 63.6%). In the TOWER study, the survival prognosis for patients achieving CRh/CRi versus CR with blinatumomab was more similar (median OS, 11.9 (95% CI, 3.9–not estimable (NE)) vs. 15.0 (95% CI, 10.4–NE) months, <i>p</i> = 0.062) than with chemotherapy (5.2 (95% CI, 1.6–NE) vs. 18.9 (95% CI, 9.3–NE) months, <i>p</i> = 0.013). Blinatumomab treatment, with only temporary and transient myelosuppression, resulted in a greater survival benefit than chemotherapy.Hagop M. KantarjianGerhard ZugmaierMonika BrüggemannBrent L. WoodHeinz A. HorstYi ZengGiovanni MartinelliMDPI AGarticleacute lymphoblastic leukemiabispecific antibodybispecific T-cell engagerblinatumomabmeasurable residual diseasemyelosuppressionNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5607, p 5607 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acute lymphoblastic leukemia bispecific antibody bispecific T-cell engager blinatumomab measurable residual disease myelosuppression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	acute lymphoblastic leukemia bispecific antibody bispecific T-cell engager blinatumomab measurable residual disease myelosuppression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hagop M. Kantarjian Gerhard Zugmaier Monika Brüggemann Brent L. Wood Heinz A. Horst Yi Zeng Giovanni Martinelli Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
description	Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph−) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL; <i>n</i> = 267) and Ph+ BCP-ALL (<i>n</i> = 45) from the TOWER and ALCANTARA studies, respectively, or chemotherapy in patients with Ph− BCP-ALL (<i>n</i> = 109) from the TOWER study; all the patients with relapsed/refractory BCP-ALL and responders achieving complete remission (CR) or CR with partial/incomplete hematological recovery (CRh/CRi) were evaluated. Event-free survival (EFS) and overall survival (OS) were assessed in patients achieving CR and CRh/CRi. Median leukocyte, neutrophil, and platelet counts increased during two blinatumomab cycles but remained low longer after chemotherapy. Among the responders, there was a trend that a greater proportion of patients achieved CR with blinatumomab (Ph−, 76.5%; Ph+, 77.8%) versus with chemotherapy (Ph−, 63.6%). In the TOWER study, the survival prognosis for patients achieving CRh/CRi versus CR with blinatumomab was more similar (median OS, 11.9 (95% CI, 3.9–not estimable (NE)) vs. 15.0 (95% CI, 10.4–NE) months, <i>p</i> = 0.062) than with chemotherapy (5.2 (95% CI, 1.6–NE) vs. 18.9 (95% CI, 9.3–NE) months, <i>p</i> = 0.013). Blinatumomab treatment, with only temporary and transient myelosuppression, resulted in a greater survival benefit than chemotherapy.
format	article
author	Hagop M. Kantarjian Gerhard Zugmaier Monika Brüggemann Brent L. Wood Heinz A. Horst Yi Zeng Giovanni Martinelli
author_facet	Hagop M. Kantarjian Gerhard Zugmaier Monika Brüggemann Brent L. Wood Heinz A. Horst Yi Zeng Giovanni Martinelli
author_sort	Hagop M. Kantarjian
title	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
title_short	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
title_full	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
title_fullStr	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
title_full_unstemmed	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
title_sort	impact of blinatumomab treatment on bone marrow function in patients with relapsed/refractory b-cell precursor acute lymphoblastic leukemia
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c231d049e90a4489be5d68650cd3c8ec
work_keys_str_mv	AT hagopmkantarjian impactofblinatumomabtreatmentonbonemarrowfunctioninpatientswithrelapsedrefractorybcellprecursoracutelymphoblasticleukemia AT gerhardzugmaier impactofblinatumomabtreatmentonbonemarrowfunctioninpatientswithrelapsedrefractorybcellprecursoracutelymphoblasticleukemia AT monikabruggemann impactofblinatumomabtreatmentonbonemarrowfunctioninpatientswithrelapsedrefractorybcellprecursoracutelymphoblasticleukemia AT brentlwood impactofblinatumomabtreatmentonbonemarrowfunctioninpatientswithrelapsedrefractorybcellprecursoracutelymphoblasticleukemia AT heinzahorst impactofblinatumomabtreatmentonbonemarrowfunctioninpatientswithrelapsedrefractorybcellprecursoracutelymphoblasticleukemia AT yizeng impactofblinatumomabtreatmentonbonemarrowfunctioninpatientswithrelapsedrefractorybcellprecursoracutelymphoblasticleukemia AT giovannimartinelli impactofblinatumomabtreatmentonbonemarrowfunctioninpatientswithrelapsedrefractorybcellprecursoracutelymphoblasticleukemia
_version_	1718412800996409344

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Ejemplares similares